AI Echocardiographic Screening of Cardiac Amyloidosis

NAEnrolling by invitationINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 28, 2024

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2026

Conditions
Cardiac Amyloidosis
Interventions
DIAGNOSTIC_TEST

EchoNet-LVH Assessment

The AI algorithm is previously described (Duffy et al. JAMA Cardiology 2022) and will remain unchanged throughout the course of the study. A pre-determined threshold based on prior experiments and analysis has been decided prior to the study. From each site, approximately 100,000 echocardiogram studies will be reviewed by EchoNet-LVH for approximately 500 patients to be flagged.

Trial Locations (4)

60190

Northwestern Medicine, Chicago

90034

Cedars Sinai Medical Center, Los Angeles

94304

Palo Alto Veteran Affairs Hospital, Palo Alto

97225

Providence Heart and Vascular Institute, Portland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Palo Alto Veteran Affairs Hospital

UNKNOWN

collaborator

Providence Heart & Vascular Institute

OTHER

collaborator

Northwestern Medicine

OTHER

lead

Cedars-Sinai Medical Center

OTHER

NCT06664866 - AI Echocardiographic Screening of Cardiac Amyloidosis | Biotech Hunter | Biotech Hunter